Daily Stock Analysis, CYTR, CytRx Corp, priceseries

CytRx Corp. Daily Stock Analysis
Stock Information
Open
0.61
Close
0.59
High
0.61
Low
0.57
Previous Close
0.60
Daily Price Gain
-0.01
YTD High
0.64
YTD High Date
Jan 16, 2019
YTD Low
0.43
YTD Low Date
Jan 2, 2019
YTD Price Change
0.07
YTD Gain
14.56%
52 Week High
2.18
52 Week High Date
Mar 16, 2018
52 Week Low
0.33
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-0.98
52 Week Gain
-62.42%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 9. 2017
2.46
Jan 18. 2017
2.60
6 Trading Days
5.81%
Link
LONG
Apr 19. 2017
3.12
Apr 20. 2017
3.33
1 Trading Days
6.73%
Link
LONG
Apr 21. 2017
3.66
Apr 27. 2017
4.04
4 Trading Days
10.25%
Link
LONG
May 25. 2017
3.66
Jun 5. 2017
4.16
6 Trading Days
13.72%
Link
LONG
Oct 31. 2017
2.16
Nov 1. 2017
2.38
1 Trading Days
9.95%
Link
LONG
Jan 22. 2018
1.83
Jan 29. 2018
1.96
5 Trading Days
7.26%
Link
Company Information
Stock Symbol
CYTR
Exchange
NasdaqCM
Company URL
http://www.cytrx.com
Company Phone
310-826-5648
CEO
Steven A. Kriegsman
Headquarters
California
Business Address
11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES, CA 90049
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000799698
About

CytRx Corp. operates as a biopharmaceutical research and development company specializing in oncology. It provides clinical development of aldoxorubicin oncology pipeline for the treatment of cancer. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.

Description

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company's product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.